SCHEMBL7214822

SCHEMBL7214822

COc1ccc([C@@H](CNC(=O)[C@H](CC(C)C)NC(=O)Cc2ccc(NC(=O)Nc3ccccn3)cc2)C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.46
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
ITGB1 P05556 3/20 0.44
ITGA4 P13612 3/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
CTSS P25774 4/20 0.43
CTSK P43235 3/20 0.43
CTSL P07711 3/20 0.43
RIOK2 Q9BVS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7470973 1.00 ANPEP (0.46) ANPEPHDAC3HDAC4HDAC1HDAC7
SCHEMBL7465560 0.92 ITGB1 (0.42) ANPEPITGB1ITGA4RAB9ANPC1
SCHEMBL7467208 0.92 ITGB1 (0.42) ANPEPITGB1ITGA4RAB9ANPC1
SCHEMBL7468112 0.86 ITGB3 (0.50) ANPEPHDAC3HDAC4HDAC1HDAC7
SCHEMBL7470798 0.82 RAB9A (0.42) ITGB1ITGA4RAB9ANPC1RIOK2
SCHEMBL7467449 0.80 ATM (0.43) ANPEPITGB1ITGA4RAB9ANPC1
SCHEMBL7466878 0.80 ATM (0.43) ANPEPITGB1ITGA4RAB9ANPC1
SCHEMBL7457312 0.80 MAPK1 (0.46) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL7467182 0.80 DGAT1 (0.45) ANPEPITGB1ITGA4RAB9ANPC1
SCHEMBL7468077 0.80 DGAT1 (0.45) ANPEPITGB1ITGA4RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624152-B2 Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases BIOGEN, INC. 2003-09-23 US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 EP claimed